Andras Farkas

Andras Farkas

Auto-generated profile, based on publicly available information

Andras Farkas

Optimum Dosing Strategies, Bloomingdale, NJ, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Critical Care
Verified
Journal Article
Closed access
SDSofie An Magriet Dhaese
Sofie An Magriet Dhaese
ATAlexander D.J. Thooft
Alexander D.J. Thooft
AFAndras Farkas
Andras Farkas
Jeffrey LipmanJeffrey Lipman
Jeffrey Lipman
AVAlain G. Verstraete
Alain G. Verstraete
JWJan J. De Waele
Jan J. De Waele

12 August 2023 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Open access
MCMing Chai
Ming Chai
JRJason A. Roberts
Jason A. Roberts
CKChristina F. Kelly
Christina F. Kelly
JUJacobus P J Ungerer
Jacobus P J Ungerer
BMBrett C. McWhinney
Brett C. McWhinney
MCMenino O. Cotta
Menino O. Cotta
Broad-spectrum antibiotics such as beta-lactams and vancomycin are frequently used to treat critically ill patients, however, a significant number do not achieve target exposures. Therapeutic drug monitoring (TDM) combined with Bayesian forecasting dosing software may improve target attainment in these patients. This study aims to describe the efficiency of dosing software for achieving target exposures of selected beta-lactam antibiotics and vancomycin in critically ill patients. A prospective cohort study was undertaken in an adult intensive care unit (ICU). Patients prescribed vancomycin, piperacillin-tazobactam and meropenem were included if they exhibited a subtherapeutic or supratherapeutic exposure informed by TDM. The dosing software, ID-ODSTM, was used to generate dosing recommendations which could be either accepted or rejected by the treating team. Repeat antibiotic TDM were requested to determine if target exposures were achieved. Between March 2020 and December 2021, 70 were included in the analysis. Software recommendations were accepted for 56 patients (80%) with 50 having repeated antibiotic measurements. Forty-three of the 50 patients (86%) achieved target exposures after one software recommendation, with 3 of the remaining seven patients achieving target exposures after 2. Forty-seven patients out of the 50 patients (94%) achieved the secondary outcome of clinical cure. There were no antibiotic exposure-related adverse events reported. The use of TDM combined with Bayesian forecasting dosing software increases the efficiency for achieving target antibiotic exposures in the ICU. Clinical trials comparing this approach with other dosing strategies are required to further validate these findings.

11 June 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
AFAndras Farkas
Andras Farkas
JSJoseph Sassine
Joseph Sassine
JMJoseph P Mathew
Joseph P Mathew
CSChristine Stavropoulos
Christine Stavropoulos
RSRon Stern
Ron Stern
GMGeorge Mckinley
George Mckinley
There is growing evidence that patients with community-onset pneumonia and recent healthcare exposure are not at equally high risk of infection with MDR organisms. An individualized approach is necessary with regard to risk assessment and choice of antibiotics. We reviewed the records of 102 patients admitted for community-onset pneumonia, before and after the implementation of a revised risk assessment programme for MDR organisms using the drug resistance in pneumonia (DRIP) score. The primary aim of the study was to identify the effects of this intervention on antibiotic days of therapy (DOT), and secondary outcomes included all-cause readmissions and time to clinical improvement. Statistical analysis was performed using generalized linear regression and Cox hazards models. Implementation of the programme resulted in a decrease in anti-MRSA (−1.44 DOT, P = 0.007) and anti-pseudomonal (−2.03 DOT, P < 0.001) antibiotic utilization, but was not associated with a significant difference in the odds of readmissions (OR 0.64, 95% CI 0.16–2.57) or in time to clinical improvement (HR 1.19, 95% CI 0.62–2.21). An individualized MDR organism risk assessment strategy using a clinical prediction score for community-onset pneumonia can decrease the utilization of broad-spectrum antibiotics without an increase in adverse outcomes.

20 March 2019 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
AFA. Farkas
A. Farkas
FLF. Lin
F. Lin
KBK. Bui
K. Bui
FLF. Liu
F. Liu
GAG. L. An
G. L. An
AYA. Yassin
A. Yassin
Pseudomonas aeruginosaand methicillin-resistantStaphylococcus aureus(MRSA) have been considered prevalent pathogens in foot infections. However, whether empiric therapy directed against these organisms is necessary, and in whom to consider treatment, is rather unclear. The aim of this study was to develop predictive algorithms for forecasting the probability of isolating these organisms in the infected wounds of patients in a population where the prevalence of resistant pathogens is low. This was a retrospective study of regression model-based risk factor analysis that included 140 patients who presented with infected, culture positive foot ulcers to two urban hospitals. A total of 307 bacteria were identified, most frequently MRSA (11.1%).P. aeruginosaprevalence was 6.5%. In the multivariable analysis, amputation (odds ratio (OR) 5.75, 95% confidence interval (CI) 1.48–27.63), renal disease (OR 5.46, 95% CI 1.43–25.16) and gangrene (OR 2.78, 95% CI 0.82–9.59) were identified as risk factors associated with higher while diabetes (OR 0.07, 95% CI 0.01–0.34) and Infectious Diseases Society of America infection severity >3 (OR 0.18, 95% CI 0.03–0.65) were associated with lower odds ofP. aeruginosaisolation (Cstatistic 0.81). Similar analysis for MRSA showed that amputation was associated with significantly lower (OR 0.29, 95% CI 0.09–0.79) risk, while history of MRSA infection (OR 5.63, 95% CI 1.56–20.63) and osteomyelitis (OR 2.523, 95% CI 1.00–6.79) was associated with higher odds of isolation (Cstatistic 0.69). We developed two predictive nomograms with reasonable to strong ability to discriminate between patients who were likely of being infected withP. aeruginosaor MRSA and those who were not. These analyses confirm the association of some, but also question the significance of other frequently described risk factors in predicting the isolation of these organisms.

4 December 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
SZSophia Zhitomirsky
Sophia Zhitomirsky
HSHendrik Sy
Hendrik Sy
AYArsheena Yassin
Arsheena Yassin
CSChristine Stavropoulos
Christine Stavropoulos
AFAndras Farkas
Andras Farkas
Gram negative bacteria (GNB) have been identified as a cause of upper extremity infections and empiric treatment directed to both gram positive and negative organisms is often recommended. Risk-based approaches to establish need for gram-negative coverage may help to minimize unnecessary drug exposure, but further information on such methods are currently lacking. The aim of this study was to identify risk factors associated with the isolation of GNB in patients with upper extremity infections. We reviewed records of patients with upper extremity infections treated in two urban hospitals between March 2018 and July 2020. Prosthetic joint infections were excluded. Baseline demographic, clinical, surgical and microbiology data was collected. Multivariable logistic regression models were screened using Akaike Information Criterion to establish the best model and risk factors associated with isolation of a GNB. We identified 111 patients, the majority of whom were male with frequent history of IV drug use. Deep wound cultures in 30 (33.3%) individuals yielded a GNB, and 80% of these cases were polymicrobial. Among the GNB, most prevalent were Enterobacterales (10.4%), HACEK group (6.39%), and Pseudomonas spp. (4.5%) (Tables 1. and 2.). Infections were mostly limited to the soft tissue structures of the hand and the forearm, with involvements of the joint and bone being second and third most common. The final model identified the use of IV medications (OR 4.14, 95% CI 1.3 - 14.46) together with prior surgery at the site of infection within the last year (OR 5.56, 95% CI 1.06 - 30.98), and having an open wound on presentation (OR 3.03, 95% CI 1.04 - 9.47) as factors independently associated with isolation of a GNB (Table 3). AUROC of 0.702 indicates acceptable model discrimination. Table 1: Baseline characteristics Table 2: Bacterial isolates Table 3: Final model Our logistic regression model identified significant predictors for isolation of GNB in upper extremity infections within this population. Results of this study will assist clinicians in making a better informed decision for the need of empiric gram negative coverage aimed to support the reduction of patient exposure to unnecessary antimicrobial coverage. External validation of the model is warranted prior to application to clinical care. Figure 1: AUROC All Authors: No reported disclosures

1 November 2021 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
AFAndras Farkas
Andras Farkas
AYArsheena Yassin
Arsheena Yassin
HSHendrik Sy
Hendrik Sy
KHKristy Huang
Kristy Huang
ISIana Stein
Iana Stein
JMJoseph Mathew
Joseph Mathew
Accurately predicting the presence of a carbapenem resistant enterobacterales (CRE) in hospitalized patients presents itself as an opportunity that would support timely initiation of CRE active agents. The aim of this study is to determine how reliably the existing risk prediction models identify patients likely to require empiric anti-CRE treatment, preliminary results of which are presented herein. A systematic search identified all existing CRE prediction models for validation in our patient population. Medical records of hospitalized patients within the Mount Sinai Health System in New York were subsequently reviewed. Data was gathered on model predictors, baseline demographics, clinical information, microbiology results, antibiotic utilization history and index infection. Besides calculating the AUROC, the main outcome of our study was to establish optimal prediction score cutoffs and false positive rates (FPR) where corresponding model performance maintains a false negative rate (FNR) of < 10%, < 20% and < 30%, respectively. 12 models were retained for validation. We identified 106 patients, 41 of which were treated for a CRE infection. Previous admission, organ transplantation, CKD, infection type, and carbapenem use were baseline variables that significantly differed between the groups treated for a CRE or non-CRE related infection (Table 1). The models ability to discriminate varied as evidenced by the AUROC range of 0.5 to 0.77 (Figure 1), suggesting the Seligmen et al. model as the overall best. When evaluated at the pre-specified FNR intervals of < 10%, < 20% and < 30%, the model by Lodise et al., Seligman et al., and Vazquez-Guillamet et al. produced the best FPR, respectively (Table 2). Table 1. Baseline characchteristics Table 2. Model Performance Figure 1. AUROCs Discriminative ability of the risk prediction models showed varying performance. The model by Lodise et al. appears to be most useful when a low risk level is deemed acceptable for failure rate, while at a moderate to high risk of missing a CRE case (20% and 30% FNR), the methods by Seligman and Vazquez-Guillamet et al. are most desirable as they minimize the chance of over-treatment. Additional work to increase sample size and to evaluate the models inter-rater reliability is currently on going. All Authors: No reported disclosures